Ptc Therapeutics PTCT

$56.42 -1.91 (-3.27%)

Valuation

Market cap
4,713,552,000
Revenue TTM
$1,730,660,000
Net income TTM
$682,640,000
P/E (trailing)
0.00
P/E (forward)
118.68
Profit margin
39.44%
Debt to equity
-14.86

Trading

Volume
952,600
Avg volume
1,150,528
Day's range
$56.18 – $58.96
Shares out
83,544,000
Stochastic %K
3%
Beta
0.52
Analysts
Moderate Buy
Price target
$98.56

Price

Company profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; T...

Show more

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 222 7000
Website
https://www.ptcbio.com
Address
500 Warren Corporate Center Drive, Warren, United States

Latest news

Stocktwits

MikeJames1255 Nov 20, 8:00 PM
$PTCT absolutely nasty price action
0 replies
dgbio Nov 13, 7:34 PM
$PTCT Italian Clinicians Contest European Withdrawal of Duchenne Muscular Dystrophy Drug Ataluren https://bioengineer.org/italian-clinicians-contest-european-withdrawal-of-duchenne-muscular-dystrophy-drug-ataluren/
1 replies
NoFomo_ Nov 10, 4:05 PM
$PTCT Two straight quarters of strong earnings, very promising guidance for next year, and management buying a significant amount of shares. Yet $PTCT is still going nowhere. It honestly feels like market makers have taken control, keeping the stock pinned to burn options. At this point, options trading should be banned. Ridiculous.
0 replies
Jblack500 Nov 9, 8:07 PM
@MaverikIT @WAJeff @cynicaloptimist $ELAN $TEM $PTCT $GILD $MRK nice gains elan and tem. Elan getting a lot of love today. Ubs pt 35, stifel pt 33, jpm pt raise from 33 to 35, piper pt 30. My target has been low to mid 30's since buying it in teens.
0 replies
Jblack500 Nov 9, 5:07 PM
$HALO $PTCT $ELAN $TEM Halo price resetting post earnings. Will continue to grow sales and reduce share count. Ptct big buyback announced last week..will be nearly 10% of float and likely put a floor in near 60. Elan nice earnings last week.
1 replies
GTA_Terminal Nov 7, 7:57 PM
Dark pool check on $PTCT: what traded off the exchanges this session. Price barely moved (-0.4%), which is what you'd expect if somebody big is building or unwinding a position quietly. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PTCT&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PTCT Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-ptc-therapeutics-ptct?utm_source=stocktwits&utm_medium=social
0 replies
MikeJames1255 Nov 5, 9:46 PM
$PTCT they bought back shares and stock already down 5%. Not sure about buybacks for a single product company. How can they be out of ideas?
0 replies
GTA_Terminal Nov 4, 4:12 AM
Unusual options activity in $PTCT. Both sides are getting paid for here. Somebody expects a move, they just don't agree which way. The biggest single trade goes out to January, so this isn't a one-day lotto ticket. Read the full article for the full details: https://globaltradersacademy.com/articles/ptc-therapeutics-ptct-stock-jumps-12-what-the-options-flow-shows?utm_source=stocktwits&utm_medium=social
0 replies